Spring has sprung at NOTL's new tulip pick farm
Started five years ago by Frank Boendermaker, TASC's pick farm originated in Fenwick, Ont., and is finally calling NOTL its permanent home.
'It really fits well here — with the wine, the tulips, the downtown area, all the beautiful hotels and restaurants. We're thrilled to be here,' Boendermaker's wife Jill McCourt told The Lake Report.
With an official opening date of April 30, the start of tulip season in Ontario, TASC's new farm, located on Line 3 Road, features 135 different varieties of tulip.
'Most people don't realize when they go to a tulip pick farm, they just think of the same ones they see in the grocery store — but we'll have so many more,' McCourt said.
TASC wasn't always such a large-scale operation. Before planting roots in NOTL for its fifth year, the flower bulb importing company had smaller farms in Fenwick and Ridgeville for prior tulip seasons.
Boendermaker immigrated to the U.S. from the Netherlands when he was 19, bringing his knowledge of tulip-growing with him.
In 2020, he and his wife began business in Canada with a five-acre farm as a way of getting people outside during the COVID-19 pandemic.
'We found how important it was for people to connect with nature during that time and how much people enjoyed it,' McCourt said.
With the farm's new permanent location, they will be able to run several events for the community — including a second grow season in August.
The late summer season will feature sunflowers, gladiolas, dahlias and more.
'We want to show people that there's a lot of other bulbs that they can put in their own gardens to have a burst of colour,' McCourt said.
Throughout the upcoming season, the farm plans to host several other special events, including paint nights, jazz evenings and wine tastings with NOTL wineries, McCourt said.
Since moving to NOTL, the farm has partnered with companies and people in town, including Juliet Dunn and the TD Niagara Jazz Festival, for Sip, Savour and Sax nights on Wednesdays.
TASC is also supporting NOTL businesses with food trucks on site, with vendors including Cheese Secrets, Sweets & Swirls and more.
'We also have someone doing some Dutch food,' McCourt said.
McCourt is excited to welcome a new crowd of people to the farm.
'Niagara-on-the-Lake welcomed us with open arms. It's been phenomenal to work with (the town),' she said.
TASC's NOTL tulip farm is located at 1173 Line 3 Rd. Tickets for the pick farm are available online at
tascllc.com
. Parking is free and the farm is accessible by bus.
juliasacco@niagaranow.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
10 minutes ago
- New York Post
Jeep and Chrysler maker Stellantis says Trump tariffs cost company $350M in first half of 2025
Jeep and Chrysler maker Stellantis on Monday reported that US tariffs have cost the company nearly $350 million as it paused production at its North American plants and lowered shipments of imported vehicles. The Dutch-based automaker — which has a portfolio that also includes Ram, Fiat and Peugeot — shipped about 109,000 fewer vehicles, a 25% drop, compared to the same period last year, the company said in releasing prelimnary data ahead of reporting earnings next week. Last year, Stellantis imported over 40% of the 1.2 million vehicles it sold in the United States, mostly from Mexico and Canada. Since Trump rolled out his tariffs in April, which include a 25% levy on foreign cars, the company idled plants in Canada and Mexico. 3 Stellantis on Monday reported a $2.68 billion loss in the first half of this year. REUTERS Overall second-quarter shipments fell by 6% compared to the same period last year, to an estimated 1.4 million vehicles, it said. The company reported preliminary losses of $2.7 billion on $83 billion in revenue for the first six months of the year, compared to a profit of $6.5 billion on nearly $100 million in revenue in the same period last year. The bulk of the losses this year was driven by $3.8 billion in pre-tax net charges, including costs tied to restructuring and the cancellation of certain programs like a hydrogen fuel cell project, the company said. Stellantis' results were 'worse than consensus, but we think poor numbers were anticipated,' Jefferies analyst Philippe Houchois wrote in a client note. Bernstein analysts said that despite a 'big' earnings miss, restructuring steps taken by Stellantis 'suggest decisive actions.' The losses underscore the tough challenges for new CEO Antonio Filosa, who was appointed in May after a disastrous performance in the company's crucial US market in 2024 forced the ouster of former boss Carlos Tavares. 3 Stellantis, whose portfolio includes Jeep, said net revenue fell to $86.5 billion — a 12.6% drop from the first six months of 2024. REUTERS Under Tavares, industry experts said Stellantis had priced itself out of the US market and failed to update popular models, leaving the company with vast numbers of unsold cars. Globally, shipments totaled 1.4 million units for the quarter, down 6% year-over-year. Filosa on Monday promised that 2025 would be 'a year of gradual and sustainable improvement' for the automaker after a 'tough first half, with increasing external headwinds.' 'Despite difficulties, it has also been six months of meaningful progress compared to the second half of 2024,' he said in a letter to employees seen by Reuters. 3 Stellantis' stock has fallen by more than 55% in the last 12 months. The slowdown in deliveries contributed to the overall revenue decline and piled additional pressure on earnings. Stellantis suspended its full-year guidance back in April. Monday's preliminary results appear aimed at resetting expectations ahead of the company's full, audited financial report, which is scheduled for release on July 29. In the meantime, the disappointing numbers have weighed on the company's stock price and investor confidence. In the last 12 months, Stellantis' stock has dipped by more than 54%. It was trading 2.55% higher on Monday morning at around $9.44 per share. With Post wires
Los Angeles Times
an hour ago
- Los Angeles Times
FDA Appoints Biotech Executive as Top Drug Regulator Under RFK Jr.
Food and Drug Administration commissioner Marty Makary has chosen former biotech executive George Tidmarsh as the agency's top drug regulator, the agency confirmed Monday. Tidmarsh, an adjunct professor of pediatrics and neonatology at Stanford University, will serve as director of the Center for Drug Evaluation and Research, one of the FDA's largest and most important divisions with a staff of about 5,700 that reviews the vast majority of new drug applications. Jacqueline Corrigan-Curay, the acting head of the CDER, recently announced she was leaving the agency. Tidmarsh, 65, was involved in the development of several approved drugs, likely making him a reassuring choice for a pharmaceutical industry that's facing pressure from the Trump administration to lower prices and move manufacturing to the US. Tidmarsh's appointment 'brings in a generally well-respected, credible industry veteran, we believe helping fill a key regulatory void,' Brian Abrahams, an analyst at RBC Capital Markets, said in a note to clients. While recent cuts at the agency have raised concerns about the FDA's drug approval process, 'we would expect Tidmarsh to be a pragmatic officer who will likely build upon current practice to ensure continuity and potentially be an advocate for the industry.' Among the controversies Tidmarsh will contend with is the agency's accelerated approval process. The use of this expedited pathway to get drugs green lit has skyrocketed in recent years and been criticized for sometimes letting unproven treatments linger on the market for too long. Advocates say speeding up the process gets drugs quickly to patients suffering from serious diseases. Tidmarsh is also primed to be a key player in reassessing the agency's approach to regulating prescription drug advertising. Health Secretary Robert F. Kennedy Jr. has long been a critic of direct-to-consumer drug advertising, and Makary has indicated that the agency is reviewing its approach to regulating such ads. During a panel on censorship and scientific speech at Stanford last year, Tidmarsh raised concerns about the FDA's inconsistent regulation of pharmaceutical products. He pointed to the agency's long-standing restrictions on off-label communication by manufacturers and questioned some vaccine makers' ads during the pandemic.'This discrepancy shows that FDA may apply free speech regulation at a whim and inconsistently,' he said. While the FDA's vaccine division has been in the spotlight recently over Covid shots, the drug division has made some of the agency's most controversial decisions. In the '90s, CDER approved language allowing opioid drugs, such as OxyContin, to be widely marketed — despite a lack of substantial evidence supporting their long-term effectiveness. The move helped pave the way for the opioid epidemic. The division also caused a firestorm after approving the Alzheimer's treatment Aduhelm that hadn't clearly been proven to work in research studies. On a recent podcast, Tidmarsh said he met Makary at a conference last fall at Stanford. It featured many people critical of restrictions and mandates during the pandemic, several of whom now have top government health jobs. Tidmarsh appears to share Makary's concerns about a lack of dissenting viewpoints in science. In a podcast about a year ago, he said academics foster a culture that is reluctant to question prevailing views and that grantmaking has become concentrated into a few hands. On LinkedIn last year, Tidmarsh wrote that 'academic science has become riddled with fraud, the time has come to root out the corruption.' He funds the Sleuth in Residence program that supports scientific fraud investigators at the website Retraction Watch, which tracks academic journals. At Stanford, Tidmarsh got both his medical degree and a PhD in cancer biology and then worked in the school's clinical faculty. He also had a series of biotech jobs, including chief executive officer for La Jolla Pharmaceutical Co., which developed a drug to treat sepsis and is now part of Innoviva Inc. Tidmarsh, who was also trained in pediatric oncology, has worked over the years to find solutions to shortages of old lifesaving cancer drugs. In an interview last year with a publication for doctors, he likened the US generic drug market to a 'wild west' where predatory contracting practices can drive out manufacturers. Langreth and Hornblower write for Bloomberg.
Business Insider
2 hours ago
- Business Insider
Top 10 countries with the highest reserves of foreign exchange and gold 2025
Countries with substantial foreign exchange and gold reserves are better positioned to preserve stability and safeguard their national interests at a period of rising economic instability, geopolitical tensions, and volatile commodities markets. Business Insider Africa presents the top 10 countries with the highest reserves of foreign exchange and gold 2025. This list is courtesy of Global Firepower. China ranks number 1 on the list. These reserves, which are composed of gold holdings and foreign currencies like the US dollar and euro, act as a vital financial buffer. Their significance is represented in international rankings like those created by Global Firepower, which monitors national capabilities like economic strength and defense readiness. Large gold and foreign exchange reserves provide a number of strategic benefits for many nations, particularly those in Africa and the Global South. They serve as a safety net in times of emergency, to start. Countries with large reserves can utilize them to stabilize their currency, pay for necessary imports, or satisfy international debt commitments without going into default, regardless of the circumstances, a sudden economic shock, a pandemic, or a decline in commodity prices. For economies that rely heavily on imports and are impacted when the native currency depreciates, this is especially important. For example, nations with more robust reserves fared better during the COVID-19 epidemic and the Russia-Ukraine conflict. Reserves also help to maintain currency stability. Reserves are a tool that central banks can employ to curb excessive currency volatility and interfere in foreign exchange markets. Furthermore, they increase investor trust and global credibility. Strong economic management and resilience are indicated by high reserves, and this can result in improved credit ratings and cheaper borrowing rates on global markets. Countries that seem prepared and fiscally sound have a higher chance of receiving loans or investments from international organizations. With that said, here are the countries in the world with the highest reserves of foreign exchange and gold, according to Global Firepower. Top 10 countries with the highest reserves of foreign exchange and gold 2025 Rank Country Reserves of Foreign Exchange and Gold by Country (2025) 1. China $3,450,000,000,000 2. Japan $1,295,000,000,000 3. Switzerland $863,892,000,000 4. United States $773,426,000,000 5. India $627,793,000,000 6. Russia $597,217,000,000 7. Taiwan $492,635,000,000 8. Saudi Arabia $457,949,000,000 9. South Korea $420,930,000,000 10. Singapore $359,835,000,000
